ClinicalTrials.gg
Not yet recruitingNCT07510646Updated Apr 3, 2026

Transcranial Photobiomodulation for Bipolar Depression

An interventional study of Vielight Neuro Rx Gamma and Sham Device in Bipolar, Bipolar Disorder (BD) and Bipolar Disorder Depression, sponsored by Vielight Inc.. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Vielight Inc. · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 134 studies in Bipolar Disorder with a site in Canada — 24 open to participants now, 28 under way, 4 of them phase 3. Bipolar Disorder · Canada.

Planned enrollment
61st of 118
40 · median 42
Started
2026
with 5 others
No phase
57 of 134
16 open now
Primary completion
2027-07
later than 12 of 27 live
Registered
125th of 134
by date

Among the 134 studies in Bipolar Disorder with a site in Canada, this one is the 61st largest by planned enrollment of the 118 interventional ones that give a count, is one of 6 that started in 2026, is one of 57 with no phase, reaches primary completion later than 12 of the 27 other live ones, and was the 125th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

24 of the 134 studies in Bipolar Disorder with a site in Canada are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 134 studies in Bipolar Disorder with a site in Canada, or all of them as a file.
02

Study summary

This study the effectiveness and safety of light therapy device targeted at the brain using a wearable device, the Vielight RX Gamma as a treatment for bipolar depression. Up to forty patients with bipolar disorder will be enrolled into the study and will either receive active treatment with the Vielight RX Gamma or sham (inactive device). They will be administered the devices in clinic 5days/week for 6 weeks. Changes in disease symptoms, cognitive function, pain, quality of life and rest EEG changes will be assessed.

Read the detailed description

Photobiomodulation (PBM) refers to the application of low levels of red or near-infrared (NIR) light to either stimulate or inhibit biological cells and tissues involving photochemical mechanisms. Transcranial PBM (tPBM), targeting delivery of light energy to the brain, is associated with increased cerebral blood flow, oxygen availability and consumption, adenoside triphophosphate (ATP) production, and improved mitochondrial activity. More recently, tPBM has demonstrated its value as a treatment for neurological and neurodegenerative conditions. Evidence of mitochondrial dysfunction in patients with BD suggests that PBM may have therapeutic benefits for patients with BD. The primary objective of this study is to confirm the safety and efficacy of using tPBM at 40Hz stimulation in improving symptoms of depression in patients diagnosed with bipolar depression.The study will be a single-blind randomized sham-controlled pilot trial with subjects receiving treatment 5 days/week for 6 weeks.

03

Conditions studied

  • Bipolar
  • Bipolar Disorder (BD)
  • Bipolar Disorder Depression

Browse trials for

Keywords

  • photobiomodulation
  • PBM
  • Vielight
  • bipolar disorder
  • bipolar depression
  • light therapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Diagnosis of bipolar depression

      • Montgomery-Asberg Depression Rating Scale (MADRS) of 24 or higher
      • Capable of providing consent
      • Currently inpatient or outpatient
      • Ability to communicate in spoken and written English fluently enough to complete the required study assessments

Exclusion criteria

Exclusion Criteria:

  • Currently in manic or mixed episode, as measured by Young Mania Rating Scale (YMRS) more than 8-10

    • Currently psychotic
    • Judged to be at serious and imminent suicidal risk
    • Currently has alcohol or substance use disorder (meeting criteria in the past 1 months)
    • Unstable medical conditions
    • Inability to consent or to complete study procedures
    • Changes in medications or use of augmentative devices and other interventions in the 4 weeks prior to the study
    • Participation in other clinical research trials that may influence primary outcomes or adherence to the proposed study
    • Current pregnancy or intention to become pregnant
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
40 participants (estimated)

Study arms

  • Sham comparator
    Sham (inactive Neuro Rx Gamma)

    Participants assigned to this arm will be administered the sham device in clinic 5 days per week for 6 weeks

    Device: Sham Device

  • Experimental
    Neuro Rx Gamma

    Treatment with Neuro Rx Gamma

    Device: Vielight Neuro Rx Gamma

Interventions

  • DeviceVielight Neuro Rx Gamma

    Participants assigned to the intervention will be administered treatment with the Neuro Rx Gamma 5 days/week in clinic

  • DeviceSham Device

    Participant assigned to the sham device will be administered the sham device in clinic 5 days/week

06

What researchers measure

Primary outcomes

  1. Montgomery-Asberg Depression Rating Scale (MADRS)

    Change in depression symptoms as measured by the Montgomery-Asberg Depression ( Rating Scale (MADRS). Scale is from 0-60, with higher score indicating high depression severity.

    Time frame: Baseline to week 6

Secondary outcomes

  1. Clinical Global Impression Scale-Bipolar

    Change in Clinical Global Impression Scale-Bipolar (CGI-BP). Scale from 1-7 with a higher means more severe illness.

    Time frame: Change from baseline to week 6

  2. Trails Making Test

    Change in score of the Trails Making Test. Scored based on the total time in seconds it takes to complete each part, meaning a lower score is better and a higher score indicates greater cognitive impairment.

    Time frame: Baseline to week 6

  3. N-Back (2-Back)

    Change in performance in N-Back (2-back)

    Time frame: Baseline to week 6

  4. World Health Disability Assessment Schedule 2.0 (WHODAS 2.0)

    Change in quality of life as measured by the World Health Disability Assessment Schedule 2.0 (WHODAS 2.0). Scores range from 0 to 100, where higher scores indicate greater disability.

    Time frame: Baseline to week 6

  5. Pain Visual Analog Scale

    Change in Pain Visual Analog Scale. The scale ranges from 0-100mm, with a higher number indicating more severe pain.

    Time frame: Baseline to week 6

  6. Rest electroencephalography (5min rest, eyes closed)

    Change in characteristic features of rest electroencephalography. This is not a scale.

    Time frame: Baseline to week 6

  7. Stanford expectancy scale ratings

    Stanford expectancy scale rating. The scale includes six items. Each of the six items is typically rated on an 11-point Likert scale (0-10), ranging from "not at all" to "extremely".

    Time frame: Baseline

  8. Young Mania Rating Scale (YMRS)

    Change in Young Mania Rating Scale (YMRS). The Young Mania Rating Scale (YMRS) has a total score range of 0 to 60. A higher value on the YMRS does indicate greater severity of manic symptoms.

    Time frame: Baseline to week 6

  9. Columbia-Suicide Severity Rating Scale (C-SSRS)

    Change in Columbia-Suicide Severity Rating Scale. The Columbia-Suicide Severity Rating Scale (C-SSRS) is a multi-part tool and does not have a fixed range, but it generally categorizes risk on a scale of 0-6 for the screener version (0=No Risk, 1-6=Increased Risk) or uses a 2-25 range for intensity of ideation. A higher values on the C-SSRS indicate more severe suicide risk/illness.

    Time frame: Baseline to week 6

Other outcomes

  1. Device-related adverse events

    Mean difference in device related adverse events between active and sham groups

    Time frame: Baseline to week 6

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jul 2027, 12 months later.

Of 363 interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 12 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2025
First posted
Apr 3, 2026
StartEst.
Jul 1, 2026
Primary completionEst.
Jul 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07510646
Lead sponsor
Vielight Inc.
Responsible party
Sponsor
First posted
Apr 3, 2026
Start date
Jul 1, 2026 (estimated)
Primary completion
Jul 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Apr 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion